Hypertension treatment in sub-Saharan Africa: a systematic review

Cardiovasc J Afr. 2023;34(5):307-317. doi: 10.5830/CVJA-2022-065. Epub 2023 May 25.

Abstract

Sub-Saharan Africa (SSA) faces the highest rate of hypertension worldwide. Blood pressure (BP) control rests on the association of lifestyle modification and antihypertensive medicines. We aimed to systematically review antihypertensive strategies implemented in SSA to achieve BP control. A systematic search beginning in 2003 was performed in MEDLINE, COCHRANE and EMBASE. We included only original and observational studies in SSA countries. Thirty studies were included from 11 countries. No study was multinational. The number of patients varied from 111 to 897 (median: 294; IQR: 192-478). Overall, 21% of patients received monotherapy, 42.6% two-drug and 26.6% three-drug combinations. Out of all the strategies, renin-angiotensin system (RAS) blockers were mostly prescribed, followed by diuretics and calcium channel blockers. In monotherapy, RAS blockers were the first to be prescribed. Only 10 articles described antihypertensive strategies beyond triple combinations. BP control was highly variable (range: 16.4 to 61.2%). Multicentre studies performed in several SSA countries are needed to ensure international guidelines actually do improve outcomes in SSA.

Keywords: antihypertensive medications; developing countries; hypertension; sub‐Saharan Africa.

Publication types

  • Systematic Review
  • Review

MeSH terms

  • Africa South of the Sahara / epidemiology
  • Antihypertensive Agents* / therapeutic use
  • Blood Pressure* / drug effects
  • Calcium Channel Blockers / therapeutic use
  • Diuretics / therapeutic use
  • Drug Therapy, Combination
  • Humans
  • Hypertension* / diagnosis
  • Hypertension* / drug therapy
  • Hypertension* / epidemiology
  • Hypertension* / physiopathology
  • Treatment Outcome

Substances

  • Antihypertensive Agents
  • Calcium Channel Blockers
  • Diuretics